Welcome to our dedicated page for Harrow Health SEC filings (Ticker: HROW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Harrow, Inc. (HROW) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures filed with the U.S. Securities and Exchange Commission. Harrow is an ophthalmic-focused pharmaceutical company whose common stock trades on the Nasdaq Stock Market, and its filings offer detailed information about its financial condition, capital structure, and material corporate events.
Harrow’s current reports on Form 8-K include disclosures about quarterly financial results, investor presentations, credit agreements, leadership changes at subsidiaries, and business development transactions. For example, recent 8-K filings describe the announcement of financial results for the period ended September 30, 2025, the entry into and terms of a senior secured revolving credit facility with a commercial bank, and the agreement to acquire, and subsequent completion of the acquisition of, Melt Pharmaceuticals, Inc., a clinical-stage company developing non-opioid, non-IV sedation therapies.
The company’s filings also document capital markets and debt activities. Harrow has reported the pricing of senior unsecured notes due 2030 in a private offering and related plans to use the proceeds to repay existing debt and redeem previously issued senior notes. Separate Form 25 filings by the Nasdaq Stock Market LLC show the removal from listing and registration of Harrow’s 8.625% senior notes due 2026 and 11.875% senior notes due 2027.
Through Stock Titan, users can follow Harrow’s 10-K annual reports, 10-Q quarterly reports, and 8-K current reports as they are made available on EDGAR. AI-powered summaries help explain the key points in these documents, including revenue trends, operating results, debt arrangements, and the terms of material agreements such as merger agreements and credit facilities. The filings page also surfaces information relevant to equity and debt investors, including unregistered sales of equity securities disclosed in connection with milestone-based consideration for acquisitions.
For investors analyzing Harrow’s ophthalmic and procedural sedation strategy, the SEC filings provide primary-source detail on transaction structures, milestone obligations, and financial covenants. Stock Titan’s tools are designed to make these complex filings easier to review by highlighting important sections and presenting concise explanations of the underlying disclosures.
Key Takeaway: Harrow Inc.’s 2025 Annual Meeting (18-Jun-2025) produced broad shareholder support on every agenda item, reaffirming governance stability without introducing immediate balance-sheet or earnings effects.
A strong quorum of 31.27 million shares (85.2 % of the 36.69 million entitled) was present. All four director nominees—Mark L. Baum, Adrienne L. Graves, Lauren P. Silvernail and Perry J. Sternberg—were re-elected with at least 98.8 % of votes cast, signalling investor confidence in existing leadership.
The new 2025 Incentive Stock and Awards Plan passed with 21.70 million ‘For’ (90.5 % of votes cast, excl. broker non-votes) versus 1.77 million ‘Against’. The plan gives the board fresh equity-compensation capacity, potentially increasing future dilution if fully utilised.
Audit matters were routine: shareholders ratified Crowe LLP for FY-2025 with 31.23 million ‘For’ (99.8 %), removing audit-continuity uncertainty. Advisory votes showed 94.1 % support for executive pay and 82.5 % support for holding a say-on-pay vote every year.
No M&A, financing, or earnings guidance was disclosed. Overall, this 8-K reflects standard corporate-governance maintenance rather than a catalyst for near-term valuation change.